The Biological Functions and Mode of Action of Transcription Factor ELF4: A Promising Target for Treating Intestinal Homeostasis Disorder-Related Diseases

TL;DR

This paper reviews the role of the transcription factor ELF4 in maintaining intestinal health and suggests it as a potential target for treating intestinal disorders.

Contribution

The paper identifies ELF4 as a novel therapeutic target for intestinal homeostasis disorders through its roles in immune modulation and barrier function.

Findings

ELF4 maintains intestinal barrier integrity and promotes microbial balance.

ELF4 modulates inflammatory responses and enhances anti-infection defenses in the gut.

ELF4 deficiency is linked to conditions like alcoholic liver disease and may offer antiviral therapeutic potential.

Abstract

Dysregulated intestinal homeostasis is a major global health threat, affecting an estimated 1–1.5 billion people worldwide with conditions like inflammatory bowel disease, chronic diarrhea, and dysmotility. The core mechanisms involve gut dysbiosis, immune dysfunction, and impaired epithelial barrier function. Targeting transcription factors, key regulators of gene expression, offers a promising strategy for precision medicine. This review synthesizes evidence highlighting epithelial transcription factor ELF4 as a crucial host protective factor. Research has demonstrated ELF4’s significant roles in maintaining intestinal barrier integrity, promoting microbial balance, modulating inflammatory responses in the gut, and enhancing anti-infection defenses. Thus, ELF4 emerges as a novel therapeutic target for restoring intestinal homeostasis and enabling precision treatment. Future research into ELF4 and its downstream pathways will further elucidate the molecular basis of intestinal diseases, paving the way for more effective therapies and offering new hope for patients suffering from these prevalent disorders.

Intestinal homeostasis disorders (IHDs), driven by food safety issues, pollution, and drug-resistant pathogens, threaten global health. Key factors in intestinal and metabolic diseases (like IBD, obesity, and liver disease) include barrier dysfunction, gut microbiota imbalance, and excessive immune activation. Transcription factors in intestinal epithelial cells are crucial regulators. ELF4, an ETS family transcription factor, plays vital roles in transcriptional regulation, impacting tumorigenesis, the DNA damage response, and the cell cycle. ELF4 deficiency exacerbates alcoholic liver disease (ALD). Significantly, ELF4 is a novel IFN-I transcription factor with antiviral capabilities. Its regulation of the type I IFN response offers new avenues for developing antiviral and anticancer strategies and managing IFN-induced autoimmune disorders. Thus, ELF4 emerges as a promising target for preventing and treating IHD-related diseases. Mechanistic studies could help identify diets or antimicrobials that activate intestinal ELF4 to combat pathogen/virus-induced intestinal diseases.

Figures